FDA Clearance Tracker · DEN160018
reSet
Last checked: Nov 20, 2026Latest source record: Sep 14, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Sep 14, 2017
De Novo granted
Time to decision
486 days
Received May 16, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN160018
- Device name
- reSet
- Applicant
- Pear Therapeutics, Inc.
- Applicant location
- Boston, MA
- Received
- May 16, 2016
- Decided
- Sep 14, 2017
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 882.5801
- Specialty
- Neurology & Neurosurgery
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN160018
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Pear Therapeutics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Somryst510(k)
K191716 · Decided Mar 23, 2020 · 271 days after receipt
Device type: Computerized Behavioral Therapy Device For Insomnia (QVO) · Neurology & Neurosurgery
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.